Fig. 3

Relative risk of acute myocardial infarction in users of blood glucose–lowering medications. IV, inverse variance. Red bars, percentage of items in the RTI item bank indicating high risk of bias; yellow bars, percentage of items at unclear risk of bias. Items with low risk of bias not shown. Denominators indicate the number of items evaluated for each study. Rosiglitazone versus metformin: Tzoulaki et al. [38] contributed the relative risk reported for combination therapy; for Loebstein et al. [35], the combination-therapy estimate was not estimable. Sulfonylureas versus metformin: Tzoulaki et al. [38] contributed the estimate for second-generation sulfonylureas